<DOC>
	<DOCNO>NCT02226757</DOCNO>
	<brief_summary>This study pilot study EGFR-mutated NSCLC patient progress standard-dose TKIs . Tumor biopsy evaluate HER2-expression . In case HER2 expression , patient participate trial obtain informed consent . Patients treated weekly paclitaxel-trastuzumab .</brief_summary>
	<brief_title>Paclitaxel-trastuzumab EGFR-mutated NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm stage IV nonsquamous NSCLC patient . Patients must detect activate EGFR mutation baseline must yet progress erlotinib , gefitinib afatinib monotherapy daily dose 150 mg , 250 mg 40 mg respectively . ( Patients unknown mutation status exhibit response agent stable disease least 6 month treatment gefitinib erlotinib also eligible ) . Rebiopsy acquire resistance TKItreatment must perform HER2overexpression ( positive immunohistochemistry stain ) must detect . There must least one measurable disease site , accord RECIST 1.1 criterion . WHO performance status 02 . Willing able comply study prescription . 18 year old . Not pregnant breast feeding willing take adequate contraceptive measure study . Ability give write informed consent patient registration . No uncontrolled infectious disease . No active malignancy . No major surgery ( exclude diagnostic procedure like e.g . mediastinoscopy VATS biopsy ) previous 4 week . No treatment investigational drug . No known hypersensitivity trastuzumabpaclitaxel No symptomatic brain metastasis . History coronary artery disease , NYHA class III IV Left Ventricular Ejection Fraction ( LVEF ) &lt; 45 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>HER2-expression</keyword>
	<keyword>EGFR-mutation</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>